Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panion & Bf BiotechTPE:1760 -0.51%75 EV-to-EBIT is 15.38 as of Aug. 30, 2026, which is 54% below its 10-year median of 33.54. GuruFocus rates TPE:1760 with a GF Score™ of 75/100 and a GF Value™ of NT$86.45 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 685 Drug Manufacturers companies, Panion & Bf Biotech ranks better than 52.12% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Panion & Bf Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$5,353 Mil.
Panion & Bf Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$334 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech EV-to-EBIT Related Terms
Panion & Bf Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Panion & Bf Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Panion & Bf Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panion & Bf Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's EV-to-EBIT falls into.
Panion & Bf Biotech's current Enterprise Value is NT$5,130 Mil.
Panion & Bf Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$334 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech (TPE:1760) has a EV-to-EBIT of 15.38 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Panion & Bf Biotech and its competitors. This is 54% below median its historical median of 33.54. Over the past decade, Panion & Bf Biotech's EV-to-EBIT has ranged from 15.25 to 654.43. According to the industry distribution chart, Panion & Bf Biotech ranks #328 out of 685 companies in the Drug Manufacturers industry, placing it in the top 47.9%.
Is Panion & Bf Biotech's EV-to-EBIT too high?
Panion & Bf Biotech's current EV-to-EBIT of 15.38 is 54% below median its 10-year median of 33.54. Over the past 10 years, this metric has ranged from a low of 15.25 to a high of 654.43. The Drug Manufacturers industry median EV-to-EBIT is 16.22. Panion & Bf Biotech's value of 15.38 is 5.2% below this industry median. Based on the distribution chart, Panion & Bf Biotech ranks #328 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Panion & Bf Biotech has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Panion & Bf Biotech ranks #328 out of 685 companies for EV-to-EBIT. This puts Panion & Bf Biotech in the upper half of its industry. The industry median EV-to-EBIT is 16.22. Panion & Bf Biotech's value of 15.38 is 5.2% below this benchmark. Historically, Panion & Bf Biotech's own EV-to-EBIT has ranged from 15.25 to 654.43 over the past decade. While the company's 10-year median is 33.54 vs. the industry median of 16.22, Panion & Bf Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.22, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panion & Bf Biotech's current EV-to-EBIT of 15.38 is 5.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Panion & Bf Biotech and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panion & Bf Biotech's current EV-to-EBIT is 15.38, which is 54% below median its own 10-year median of 33.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$86.45, compared to a current price of NT$58.30 — trading 32.6% below its estimated fair value. The current EV-to-EBIT is 15.38, which is 54% below median its 10-year median of 33.54 and 5.2% below the Drug Manufacturers industry median of 16.22. Panion & Bf Biotech's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current EV-to-EBIT is 15.38 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$58.30 is trading 32.6% below its estimated GF Value™ of NT$86.45.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
EV-to-EBIT: 15.38 (54% below median its 10-year median of 33.54)
GF Value™: NT$86.45 vs. price of NT$58.30 (32.6% below fair value)
Industry Position: 5.2% below the Drug Manufacturers median (#328 of 685)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
75GF Score
Get the complete analysis for TPE:1760
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
